ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
9.79
-0.21 (-2.10%)
Jul 16, 2025, 4:08 PM HKT

HKG:1541 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
74.150.390.545.07
Other Revenue
5.397.315.158.74
79.547.75.6913.81
Revenue Growth (YoY)
933.61%35.24%-58.79%-
Gross Profit
79.547.75.6913.81
Selling, General & Admin
64.8280.4292.848.32
Research & Development
322.76291.94277.35175.95
Operating Expenses
387.58372.37370.14224.27
Operating Income
-308.04-364.67-364.45-210.47
Interest Expense
-3.45-1.52-0.79-0.89
Interest & Investment Income
6.3810.89.511.64
Currency Exchange Gain (Loss)
1.790.126.11-9.13
Other Non Operating Income (Expenses)
-0.02-25.92-73.27-514.83
EBT Excluding Unusual Items
-303.34-381.22-402.89-733.67
Gain (Loss) on Sale of Investments
14.151.76--
Gain (Loss) on Sale of Assets
---0.56
Asset Writedown
-27.4---
Other Unusual Items
---0.17
Pretax Income
-316.59-379.46-402.89-732.95
Earnings From Continuing Operations
-316.59-379.46-402.89-732.95
Minority Interest in Earnings
0.74---
Net Income
-315.86-379.46-402.89-732.95
Net Income to Common
-315.86-379.46-402.89-732.95
Shares Outstanding (Basic)
37736233286
Shares Outstanding (Diluted)
37736233286
Shares Change (YoY)
4.24%9.05%284.99%-
EPS (Basic)
-0.84-1.05-1.21-8.50
EPS (Diluted)
-0.84-1.05-1.21-8.50
Free Cash Flow
-138.44-370.25-261.93-231.24
Free Cash Flow Per Share
-0.37-1.02-0.79-2.68
Gross Margin
100.00%100.00%100.00%100.00%
Operating Margin
-387.30%-4739.09%-6405.13%-1524.23%
Profit Margin
-397.12%-4931.24%-7080.74%-5308.15%
Free Cash Flow Margin
-174.06%-4811.50%-4603.41%-1674.69%
EBITDA
-297.77-352.26-352.54-202.69
D&A For EBITDA
10.2812.4111.917.77
EBIT
-308.04-364.67-364.45-210.47
Source: S&P Global Market Intelligence. Standard template. Financial Sources.